STO Meeting to Focus on Personalized Cancer Care
By Jeremy Summers, NCBiotech Writer
Most doctors agree that personalized medicine is the way of the future, especially when it comes to serious diseases, such as cancer.
The shift towards personalized cancer care is exactly why the Society for Translational Oncology (STO) will make “Personalizing Cancer Diagnosis and Treatment" the focus of their third annual meeting later this month.
The North Carolina Biotechnology Center recently awarded the STO $5,000 to be used for the event.
The meeting will take place October 20-21 at the University of North Carolina at Chapel Hill’s Lineberger Comprehensive Cancer Center at the Rizzo Center in Chapel Hill.
"Devoting our national meeting to personalized cancer care illustrates how far this area of research has proceeded from dream to reality," said Hy Muss, M.D., professor of medicine and director of the Geriatric Oncology program at UNC. “Our program presents an unparalleled lineup of leading researchers, who will discuss the impact of genetic and molecular techniques on cancer management."
The two-day program will explain how translational research can open the way to personalized cancer care. The agenda includes expert updates on timely topics, such as using molecular markers in the clinic, management of limited metastases and new approaches to cancer imaging.
Speakers will also focus on aging and cancer, current issues in cancer screening, targeted therapies for hematologic malignancies and implementing Commission on Cancer Survivorship standards.
Highlights of the program include:
- Charles E. Perou, Ph.D., May Goldman Shaw Distinguished Professor of Molecular Oncology and Professor of Genetics at the UNC School of Medicine’s Pathology and Laboratory Medicine, will speak on "Development and Validation of Genomic Biomarkers."
- Shelley Earp, M.D., Lineberger Professor and director of the UNC Lineberger Comprehensive Cancer Center, will discuss "The Impact of Genomic and Signaling Research on Clinical Research."
- Richard L. Schilsky, M.D., will give a lecture on “Publicly Funded Clinical Trials and the Future of Cancer Care." Schilsky, professor of medicine and section chief of Hematology/Oncology at the University of Chicago Department of Medicine, will receive the 2012 Bob Pinedo Cancer Care Prize in recognition of his clinical and research leadership in the areas of gastrointestinal cancers and cancer pharmacology. His lecture will be published by the STO’s official peer-reviewed journal, The Oncologist.
"We invite all oncology clinicians, researchers, NPs, PAs, nurses, trainees, and anyone involved in cancer care to join us for these stimulating presentations," said Dr Muss. "It's a great opportunity to meet and exchange ideas with your colleagues—and to get a glimpse into some of the ways personalized medicine will affect your work as it positively impacts your cancer patients."